Illustration: Binay Sinha
The Betadine site in the USA disclaims its efficacy against Covid-19.
(1) However, several recent studies show that povidone-iodine is an effective virucidal in the nose and mouth, including against the SARS-CoV-2.
(2) The citations below report virucidal activity against SARS-CoV-2, and reduction in the severity of early-stage infection by limiting the viral load.
Established practice and several studies confirm that povidone-iodine is effective and safe, excluding certain categories. Could this not be promoted as a possible prophylactic? With evidence, as in the citations below, barring compelling reasons to the contrary, the authorities could decide on its inclusion in our protocol.
(b) Ivermectin is in the protocol of the Uttar Pradesh health department for healthcare professionals as a preventive, and along with doxycycline for early-stage treatment. This is despite WHO’s statements not supporting its use. Ivermectin has been used for years all over the world to treat children and adults for roundworm and intestinal parasites, as well as for skin diseases such as scabies. If one or both are effective and generally considered safe with certain exclusions, could experts evaluate including these in preventive protocols? This would be in addition to vaccination, masking, distancing, and hand-sanitisation. If validation is required, the authorities could consider possibly facilitating trials.
Early-stage treatment Apart from Ivermectin (to be considered), the ayurvedic practice of coconut oil “pulling”, or swishing/lavaging in the mouth, has undergone trials in the Philippines and Indonesia. Second, trials are reportedly under consideration here for an inhaled recombinant interferon. Virgin coconut oil has been studied by the Philippines for medicinal purposes for decades. Reports on its use for treatment against Covid-19 were published from late 2020. The two citations indicate their findings for early-stage treatment.
(3) Bolstering Immunity — Interferon Beta-1a (SNG001): In 2003, faculty members from the University of Southampton started a company, Synairgen, for drug discovery and biotechnology in respiratory diseases. In 2009, they developed an inhaled form of recombinant interferon beta-1a, SNG001, patented in the USA as IFN-beta. This was for people with asthma and with chronic obstructive pulmonary disease, who are especially susceptible to seasonal colds and the flu caused by coronaviruses such as the Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV), and the Middle East Respiratory Syndrome (MERS). SNG001 works by providing localised concentrations of the immune protein to strengthen a user’s defences.
Interferon beta-1a in injectable form has been in use since the 1990s for the treatment of multiple sclerosis. Subsequently, it was found to be effective against SARS-CoV, MERS, and recently, SARS-CoV-2. For acceptance in treating Covid-19, it must clear successive trials as must any medication. These are expensive, difficult, and time consuming. The difficulties beyond high costs include the availability of suitable candidates, trained professionals, and time. Trials are also often delayed because of staffing shortages, space-material-and-funding constraints, and reluctant or unavailable patients. Sometimes, trials are called off for reasons such as insufficient enrolment. These factors have delayed SNG001’s deployment so far, despite a good safety record.
Encouraging Phase 2 results were announced in mid-2020,4 but it has taken a year to get Phase 3 trials going in about 20 countries, aiming for over 600 patients. In India, the Subject Expert Committee is reportedly evaluating a proposal for clinical trials. Could this product be considered for immediate use under medical supervision?
Government-sponsored trials The Philippines government has championed trials such as of virgin coconut oil, Ivermectin, and Melatonin.
(4) Their example is inspiring, although the small sizes detract from the potential gains. Perhaps our experts could consider whether Ivermectin as a preventive and for early-stage treatment needs validation through trials here, or could be included in our protocols.
It would help to have a public advisory on Betadine gargles and nasal spray if they are effective, and likewise for Ivermectin. If possible, advice on the early-stage use of inhaled corticosteroids (Ciclesonide or Budesonide) to protect the lungs and airways would also be very helpful.
shyamponappa@gmail.com
1:
https://betadine.com/covid-19/ 2:
https://journalotohns.biomedcentral.com/articles/10.1186/s40463-020-00474-x;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341475/;
https://pubmed.ncbi.nlm.nih.gov/32608097https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2770785 3:
https://fnri.dost.gov.ph/index.php/programs-and-projects/news-and-announcement/800-virgin-coconut-oil-vco-study-results-on-covid-19-suspect-and-probable-cases-released-by-dost-fnri;
https://cnnphilippines.com/news/2021/4/16/virgin-coconut-oil-COVID-19-patients.html 4:
https://clinicaltrials.gov/ct2/show/study/NCT04385095